Hantz Financial Services Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 13.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,369 shares of the company’s stock after purchasing an additional 16,063 shares during the period. Hantz Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $5,056,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Scarborough Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the first quarter valued at $26,000. Financial Freedom LLC acquired a new position in Novo Nordisk A/S during the third quarter valued at $30,000. Root Financial Partners LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $32,000. Continuum Advisory LLC purchased a new stake in Novo Nordisk A/S in the 2nd quarter worth about $38,000. Finally, Latitude Advisors LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $38,000. Institutional investors and hedge funds own 11.54% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Jefferies Financial Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Barclays restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. Finally, Berenberg Bank restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.44.
Get Our Latest Report on Novo Nordisk A/S
Novo Nordisk A/S Stock Performance
Shares of NYSE NVO opened at $41.60 on Tuesday. The business’s 50-day moving average price is $39.99 and its two-hundred day moving average price is $43.24. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.84 and a quick ratio of 0.64. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a market capitalization of $185.73 billion, a P/E ratio of 10.45, a price-to-earnings-growth ratio of 1.40 and a beta of 0.70.
Novo Nordisk A/S News Summary
These are some of the NVO news items that stood out recently:
- Positive Sentiment: A late-stage trial found Wegovy reduced BMI in children ages 6 to under 12 with obesity. If supported by further regulatory progress, this could open a new patient population, as no medicines are currently approved for this age group. Novo says Wegovy injection lowers BMI and obesity rates in children in trial
- Neutral Sentiment: Novo presented research suggesting amylin-based medicines may help preserve bone health during weight loss. The findings support ongoing research but are not evidence of an approved treatment benefit. Novo presents preclinical and human data on bone health
- Negative Sentiment: Competition remains a risk for Novo’s obesity-drug pipeline, including pressure from a fast-moving rival in China; the positive trial news does not resolve the challenge of converting pipeline progress into durable commercial growth. Novo Nordisk’s Pipeline Progress Collides With a Fast-Moving Rival in China
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Recommended Stories
- Five stocks we like better than Novo Nordisk A/S
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
